Control of IGFBP-2 expression by steroids and peptide hormones in vertebrates

Andreas Hoeflich1 *, Elisa Wirthgen2, Robert David3, Carl Friedrich Classen4, Marion Spitschak1 and Julia Brenmoehl1

1 Institute of Genome Biology, Leibniz Institute for Farm Animal Biology (FBN), Dummerstorf, Germany
2 Ligandis GbR, Gülzow, Germany
3 Reference and Translation Center for Cardiac Stem Cell Therapy, Rostock, Germany
4 Pediatric Oncology, University Children’s Hospital, Rostock, Germany

INTRODUCTION

Shortly after the identification of IGFBP-2 (1), it was realized that its expression both in liver and ovary is induced by E2 (Table 1) in hypophysectomized rats (11). Notably, hypophysectomy increased IGFBP-2 mRNA levels in the liver but decreased IGFBP-2 gene expression in the ovary. In the following 10 years of IGFBP-2 research, particular interest was taken in the somatotropic control of IGFBP-2 (8). However, it also was realized soon, that the gonadotropic axis may play a particular role in the control of IGFBP-2 expression (12). Just recently, Foulstone and coworkers have identified a feedback loop between IGFBP-2 and the ERα (estrogen receptor-alpha), whereby both factors can mutually induce gene expression of each other (13). This particular finding further underlined the current need for a detailed meta-analysis that is dedicated to the question which factors presently are known to control expression of IGFBP-2.

IGFBP-2 PROMOTER REGION

First of all, tissue- and stage-specific expression patterns of IGFBP-2 are defined by endogenous stimulatory or repressor promoter elements within the IGFBP-2 gene. The promoter region of the gene encoding IGFBP-2 contains putative Sp1 binding sites (1, 85–87), potential response elements for E2 and P4 receptors, and overlapping sequences for albumin D-box binding (88). Kwak et al. have studied the structural basis for the stage-specific expression of IGFBP-2 in the porcine endometrium during pregnancy and identified two novel cis-elements in the promoter region of the IGFBP-2 gene (89). In this study, an endometrial 34-kDa nuclear binding protein was characterized with potential repressor functions for IGFBP-2 gene expression. These might confer site- and stage-specific expression of IGFBP-2 during pregnancy. Furthermore, a distal enhancer-like region, identified earlier in hepatic HepG2 cells (90) is active in the porcine endometrium (89). Four putative binding sites for NF-κB have been identified in lung alveolar epithelial cells isolated from rats that were exposed to oxygen (73). This finding by Cazals and coworkers may provide the functional basis for the effects of hyperoxia or hypoxia on IGFBP-2 expression described so far (74–76, 81). In small cell lung cancer cell lines, a proximal E-box was identified that binds NeuroD and thereby induces IGFBP-2 expression (77). In 11 out of 12 primary small cell lung cancer tissues assessed, the IGFBP-2 promoter was present in an unmethylated form, which confirms higher gene expression in comparison with other histological subtypes (77). Since NeuroD is expressed also in other neuroectodermal cells, NeuroD-dependent induction of IGFBP-2 expression was discussed also for retinoblastomas, medulloblastomas, or neuroblastomas (77). However, also prostate carcinoma cells are known to express NeuroD (91) and, as discussed further down, also IGFBP-2. In human breast cancer cells (MCF-7), Mireuta and coworkers could demonstrate that the proximal promoter region of IGFBP-2 is activated by an IGF-I/Pi3K/AKT/mTOR-dependent manner via an increase of nuclear Sp1 (44). The authors discussed the potential use of Sp1 inhibitors particularly in cancers that highly express IGFBP-2. Two potential androgen binding sites have been identified via bioinformatic analysis of the region upstream from the
IGFBP-2 transcription initiation site that may explain the effects of androgen treatment on IGFBP-2 gene expression as demonstrated in prostate cancer cells (57, 58).

**CONTROL OF IGFBP-2 EXPRESSION IN THE BRAIN**

More than 20 years ago, Pons and Torres-Aleman found that E2 significantly increases protein levels of IGFBP-2 in cultures of hypothalamic neurons isolated from rats (21). *In vivo*, application of E2 to ovariectomized rats also increased IGFBP-2 immunoreactivity in tanyocytes and other ependymal cells of the hypothalamus (22). On the other hand, P4 led to reduced IGFBP-2 protein levels in the apical membrane of tanyocytes in the same model. In both reports, functional interaction of steroids and the IGF-system was discussed. Also in the anterior pituitary glands from sheep (23), pigs (24), or rats (25) E2 increased IGFBP-2 levels. A positive effect of E2 on IGFBP-2 mRNA expression was present in MtT/S and GH3 cell lines established from rat pituitary adenomas (18). Notably, E2 seems to be permissive for steady state IGFBP-2 levels in the anterior pituitary since reduction of estrogens by use of anastrozole in boars decreased expression of IGFBP-2 (92). In contrast, DHEA increased IGF-I expression in the hypothalamus of rats but did not affect expression of IGFBP-2 (93). Estradiol further increased expression of IGFBP-2 mRNA in the hippocampus of ovariectomized rats (18) or in the hippocampus from normal mice 1 h after injection (19). Interestingly, also mice subjected to neonatal isolation had reduced hippocampal IGFBP-2 mRNA

---

**Table 1 | Cell- and tissue-specific control of IGFBP-2 expression in vertebrates.**

| Tissue/cell type | Species | Factor | Effect | Reference |
|------------------|---------|--------|--------|-----------|
| Brain            | ch      | Fasting| –      | (14)      |
| Astrogial cells  | ra      | IGF-I, II, insulin | + | (15) |
| Cortex           | rat     | E2, lithium | – | (16, 17) |
| Hippocampus      | ra, mo  | E2 | + | (18, 19) |
| ctd              | ra      | Stress  | – | (20) |
| Hypothalamus     | ra      | E2 | + | (21, 22) |
| Pituitary        | ov, pi, ra | E2 | + | (18, 23–25) |
| Ovaries          | ra, mo  | DES, SSAT | + | (11, 26) |
| Follicle         | bo, ov, ho, ctd fi | FSH, P4, GHRH, leptin | + | (27–29) |
|                 | ctd     | Leptin, E2, FSH, insulin | + | (30–32) |
|                 | ctd     | A, LH, activin, IFγ | + | (33, 34) |
|                 | ctd bo, fi | PGF2a, IGF-I, E2 | – | (27, 35, 36) |
| Uterus           | pi, ra, mo | P4, relaxin, E2, SSAT | + | (26, 37–39) |
| Endometrium      | hu, ap  | E2, P4 | + | (40–42) |
| Vagina           | mo      | E2 | + | (43) |
| Breast           | hu, mo, ra | IGF-I/PI3K, E2 | + | (43–45) |
| Cancer           | hu      | IGF-I/PI3K, E2, P4 | + | (46–48) |
| Cancer           | hu, ra  | E2 | – | (49–51) |
| Prostate         | ra, hu  | Antiandrogen | + | (52, 53) |
| Stromal          | hu      | T and DHT | + | (54) |
| Cancer           | hu      | DHEA, T, DHT, E2 | + | (55, 56) |
| Cancer           | hu      | A, vitamin D | – | (57–60) |
| Leydig cells     | ra      | hCG | – | (61) |
| Liver            | ra, mo  | DES, SSAT, leptin, fasting | + | (11, 26, 62–67) |
| ctd              | ov, ra  | T, insulin | – | (68–70) |
| Bone             | ra      | Mechanical loading | + | (71) |
| Kidney           | hu, mo  | IGF-I, SSAT | + | (26, 72) |
| Lung             | hu      | NF-kB, NeuroD, RA, O2 | + | (73–77) |
| Cancer           | hu      | IGF-I | + | (78) |
| Spleen           | ra      | GH | + | (79) |
| Colon            | hu      | Vitamin D | – | (80) |
| Retina           | ra      | O2 | + | (81) |
| Gizzard          | ch      | Insulin | – | (82) |
| Fin              | fi      | Androgen | + | (83) |
| Myoblasts        | mo      | IGF-I | + | (84) |
| Fibroblasts      | hu      | E2 | + | (85) |

hu, human; ap, ape; pi, pig; ov, ovine; bo, bovine; ra, rat; mo, mouse; co, cony; ch, chicken; fi, fish; E2, estradiol; P4, progesterone; DES, diethylstilbestrol; SSAT, spermidine/spermine N1-acetyltransferase; FSH, follicle stimulating hormone; GHRH, GH releasing hormone; PGE, prostaglandin F; DH/T, dihydro/testosterone; DHEA, dehydroepiandrosterone; RA, retinoic acid; LH, luteinizing hormone; IFγ, interferon gamma; hCG, human chorionic gonadotropin; ctd, continued.
expression in adulthood when exposed to restraint stress (20). During hormone replacement therapy, E2 downregulated IGFBP-2 mRNA in the frontal cortex of ovariectomized rats (16). IGFBP-2 mRNA expression was robustly down regulated also by lithium in primary cell cultures from rat cortices (17).

The important role of IGFBP-2 in malignant brain tumors, particularly glioblastoma, has already been mentioned. Reactivation of IGFBP-2 expression in glioblastoma multiforme was discussed in a context of defect astrocyte differentiation and PI3K/AKT activation (94–96). Conversely, a stable knockdown of IGFBP-2 resulted in decreased invasiveness, decreased saturation density of the cells in vitro, and decreased tumorigenicity in nude mice (97).

A strong inverse relationship between elevated IGFBP-2 levels and low p16INK4a indicates a negative regulatory function of p16INK4a for IGFBP-2 (98) similar to the negative correlation of IGFBP-2 mRNA and PTEN expression levels found both in glioblastomas and prostate cancers, implicating IGFBP-2 as a biomarker for PTEN status (95). This may be in concordance with an observation of E2-induced apoptosis of glioblastoma cells (99).

The inverse relationship between IGFBP-2 and PTEN expression is not restricted to malignant cells and has been described also during osteoclast differentiation (100).

CONTROL OF IGFBP-2 EXPRESSION IN FEMALE REPRODUCTIVE TISSUES

Hormone replacement therapy over 15 months to postmenopausal women revealed a negative effect of E2 on serum IGFBP-2 concentrations (101). Also in human adolescents with constitutional tall stature, E2 reduced serum IGFBP-2 concentrations 3 and 6 months after starting the therapy (102). In contrast, in aged women and men supplementation of sex steroids over a period of 6 months revealed no effect of a hormone replacement therapy or testosterone on IGFBP-2 serum levels (103). In human granulosa cells, LH, activin, and interferon gamma increased expression of IGFBP-2 (33) and insulin and androstenedione increased secretion of IGFBP-2 into cell conditioned media (34). After the preovulatory surge of LH, when steroid levels are low, an inverse relationship between follicular IGFBP-2 concentrations and steroid (E2, androstenedione and P4) concentrations has been described in sows already in 1992 (104). FSH increased whereas prostaglandin F2a decreased IGFBP-2 concentrations in bovine ovarian follicular fluid and low levels of IGFBP-2 in E2-active follicles suggested a role of IGFBP-2 for aromatase activity (27). By contrast, P4 treatment in cattle increased protein levels of IGFBP-2 in follicular fluids (28). In equine granulosa cells, both E2 and FSH induced expression of IGFBP-2 in vitro (30). Furthermore, in follicles, also the GH/IGF axis is involved in the control of IGFBP-2 expression. Application of growth hormone releasing hormone in cattle increased IGFBP-2 in the circulation and in the fluid from subordinated but not from dominant follicles (29). As described earlier for E2, also human recombinant IGF-I decreased IGFBP-2 mRNA expression and protein levels in granulosa cells and the oocytes from cultures bovine antral follicles in a stage- and dose-specific manner (35). In addition, granulosa cells from bovine follicles but not the oocyte have been shown to produce an IGFBP-2 protease (105). Thus, also IGFBP-2 protein stability is under active control in bovine follicles. Finally, leptin infusion for 3 days in cycling ewes increased follicular IGFBP-2 mRNA expression although this effect may be related to other hormones since at the same time insulin and FSH serum concentrations were increased while those of E2 were reduced (31).

IGFBP-2 secretion is stimulated by E2 and P4 in human endometrial stromal cells and in endometrial explants from baboons (40, 41). Short-term E2/P4 treatment of ovariec-
tomized monkeys over 2 weeks increased IGFBP-2 mRNA in the myometrium in response to E2 and to a higher degree after treat-
ment both with E2 and P4 (42). High amounts of IGFBP-2 mRNA are found in the porcine uterus (106), which might be related to the specific IGFBP-2 promoter configuration as summarized above (88). Progesterone increased gene expression of IGFBP-2 in pig uteri while E2 slightly reduced mRNA levels of IGFBP-2 (37). Notably, the trophic effects of relaxin administration on uterine weight in pigs were accompanied by robust increase of IGFBP-2 as found as a band doublet in uterine flushes (38). High IGFBP-2 levels in earlier but not in later phases of the estrus in pigs are potentially due to kallikrein/matrix metallopro-
teases (107). In fact, kallikrein, matrix metalloprotease 3, or plasminogen activator were sufficient to rapidly degrade IGFBP-
2 in uterine flushes or breast milk from pigs (107) or humans (108), respectively. Six hours after E2 injection in mice, IGFBP-
2 mRNA expression was increased in the mammary gland but even more in the vagina (43). Similarly, E2 treatment significantly increased IGFBP-2 mRNA levels also in uteri of ovariec-
tomized rats (39). A robust increase of IGFBP-2 gene expression was fur-
ther found in uteri from mice characterized by transgenic spermi-
midine/spermine N1-acetyltransferase (SSAT) expression (26).

Steroid control of IGFBP-2 is also observed in non-mammalian species as gonadotropin for IGFBP-2 mRNA in de-yolked follicles from the rainbow trout (32) whereas E2 decreased IGFBP-2 mRNA expression in the orange-spotted grouper (36).

CONTROL OF IGFBP-2 EXPRESSION IN BREAST CANCER CELLS

In human breast cancer cells (MCF-7), IGF-I potently induced expression of IGFBP-2 (46) and E2 enhanced the effect of IGF-I with its basal activity being on a lower level if compared to IGF-I (47). Martin and Baxter further demonstrated that both the effects of IGF-I and E2 were mediated by the PI3/AKT pathway since inhibitors of IGF1R, PI3K, and mTOR blocked the basal effects of IGF-I and E2 (47). Also in mammary glands from rats, E2 increased mRNA expression of IGFBP-2 mRNA (45), while in pseudo-pregnant pigs E2 injection did not affect mammary IGFBP-2 mRNA expression (109). In invasive (MCF-7/6) or in breast cancer cell lines adapted to low serum concentrations (MCF-7/S0.5) (49, 50) and in Fischer rat mammary adenocar-
cinoma cells (51), E2s suppressed intracellular and/or secreted levels of IGFBP-2. Nevertheless, secretion of IGFBP-2 was lower in ER-negative breast cancer cells compared to ER-positive cells indicat-
ing a positive or at least a permissive effect of ER on IGFBP-2 expression in mammary cells (110). Therefore, similar to cells from the brain a synergistic effect of E2 and P4 on IGFBP-2 secretion was found in breast cancer explants (48). Since this was true only for hormone-sensitive but not for hormone-insensitive samples,
it also supports at least a permissive role of ER for the functional relationships between E2- and P4-signaling on the one hand and IGFBP-2 expression on the other. Furthermore, IGFBP-2 is highly expressed by antiestrogen-resistant breast cancer cell lines (111) and in antiestrogen-resistant RUS8R-1 cells, IGFBP-2 expression was suppressed by E2 but massively stimulated by pure antiestrogen (50). Therefore, an indirect effect of E2 and the interaction of estrogens and IGFs has been suggested (49). In fact, a dedicated review discusses the crosstalk between IGFs and E2 (112) with E2 being introduced as an enhancer of IGF-signaling pathways in breast cancer. This kind of view was further elaborated and thus supported by the work of Chan et al., who described significant activation of IGF1R, IRS-1 and -2, AKT, and PI3K in response to E2 in the rat mammary gland (45).

CONTROL OF IGFBP-2 IN PROSTATE CELLS

In primary human prostate stromal cells and in human prostate cancer cells (LNCaP), androgens and in part also E2 significantly induced IGFBP-2 mRNA expression (54–56). Flutamide, an androgen receptor antagonist, blocked androgen-dependent induction of IGFBP-2 expression (54). Also antisense oligonucleotides or antiandrogen treatment reduced gene expression of IGFBP-2 in LNCaP cells (113). It was speculated, that the effects of DHT and T are mediated by the AR. Looking at the level of protein, it was demonstrated that androgen treatment rapidly decreased IGFBP-2 levels in LNCaP cells (59). Notably, negative androgen regulation of IGFBP-2 secretion involved extracellular proteolytic cleavage (59). A reduction of IGFBP-2 proteolysis in androgen-insensitive prostate carcinoma cells increased the metastatic potential in that study. Androgen-dependent regulation of IGFBP-2 mRNA expression might be established by means of the IGFBP-2 promoter specifically, as stated earlier, but also by an effect on global protein translation; unexpectedly, androgen treatment of prostate carcinoma cells for an extended period of time (48 h) downregulated the polysomal fraction of mRNA and thus global protein synthesis (57). Further supporting negative effects of androgens, castration induced gene expression of IGFBP-2 in the rat ventral prostate (114). Also antiandrogenic treatment increased tissue levels of IGFBP-2 in human patients (52) or in rats (53). Therefore, reports are available that demonstrate or suggest positive or negative (58) effects of androgens both on mRNA and protein levels of IGFBP-2 depending on the physiological condition in prostate cells.

CONTROL OF IGFBP-2 BY DIET AND INSULIN

Zapf et al. performed the initial study on hormonal control of IGFBP-2 by GH and IGF-I (115). In this study, GH suppressed expression of IGFBP-2 while IGF-I increased this particular IGFBP as demonstrated by Western ligand blotting. Notably, GH suppressed the effect of IGF-1 on IGFBP-2 concentration. After development of a specific radioimmunoassay by Blum and coworkers (116), higher levels of IGFBP-2 have been quantified during GH deficiency and IGF-I administration whereas reduced IGFBP-2 levels were present in acromegalic patients. An inverse relationship between IGFBP-3 and IGFBP-2 was diagnosed (116), indicating that GH is a suppressor of IGFBP-2 expression. This finding was repeatedly confirmed by others and may represent the basis for altered IGFBP-2 levels during fasting, in aging, or impaired liver function as suggested, e.g., by Bannink and coworkers (117). Exogenous GH downregulates IGFBP-2 in humans (117–119), whereas impaired GH receptor signaling in mice (120) elevated IGFBP-2 serum levels. Although not confirmed as a rule (121, 122), the strength of the inverse relationship between GH and IGFBP-2 and its bidirectional nature suggested the use of IGFBP-2 levels as a biomarker to monitor GH-doping (123) or IGF/IGFBP-3 misuse in male and female athletes (124). Interestingly, testosterone blocked the negative effects of growth hormone on IGFBP-2 levels in men (103) and in GHR-deficient mice testosterone increased serum levels of IGFBP-2 (125). Conditional effects of GH have been described with more suppressive effects on IGFBP-2 levels in lean versus obese sheep (126). To date, exclusively in the spleen from juvenile rats exogenous GH stimulated gene expression of IGFBP-2 in that particular tissue (79).

IGF-I increased IGFBP-2 in human subjects (121, 127), in human embryonic kidney fibroblasts (72), in human lung adenocarcinoma cells (78), in transgenic rabbits (128), in rat astroglial cells (135), or in mouse C2C12 myoblasts (83). Administration of pegylated IGF-I in mice increased serum levels of IGFBP-2 up to 30µg/ml, which corresponds to an increase of 1–2 magnitudes (129). Positive correlations of serum levels between IGF-II and IGFBP-2 have been frequently observed, e.g., in human subjects (116) or in IGF-II transgenic mouse models (130, 131). Thus, also IGF-II has been considered as a major regulator of IGFBP-2 expression. In the medulla oblongata of IGF-II transgenic mice, protein levels of IGFBP-2 were 10-fold upregulated if compared to non-transgenic mice (132). IGF-II also increased secretion of IGFBP-2 by primary rat astroglial cells (135). An interaction of IGF-I and estrogens has been discussed in women with anorexia nervosa (133). In that setting, E2 reduced IGF-dependent increase of IGFBP-2, which was discussed in a context with higher levels of free IGF-I in the presence of estrogens.

CONTROL OF IGFBP-2 EXPRESSION BY DIET AND INSULIN

IGFBP-2 has been provided as an antidiabetic and antiobesity protein by the pioneer work of Wheatcroft and coworkers (134). This finding was confirmed and leptin was shown also to stimulate hepatic expression of IGFBP-2 (62). Accordingly, an important role of IGFBP-2 for metabolic homeostasis has been discussed (135). On the other hand, in humans serum concentrations of IGFBP-2 can be increased by protein or carbohydrate intake (136–138). In addition, also single supplementations, e.g., lycopene in humans (139), or vitamin D analogs in cancer cell lines (60, 80) can induce or repress IGFBP-2 concentrations. Serum levels of IGFBP-2 were positively associated with insulin infusion in humans (140) and negatively correlated in dairy cows (141, 142). With exceptions (121), fasting increased serum levels of IGFBP-2 from humans to chicken and re-feeding normalized high fasting IGFBP-2 serum levels (130, 143–146). So far, in catfish, fasting did not affect IGFBP-2 expression (147). Altered serum levels may be due to hepatic expression of IGFBP-2 mRNA, which is increased in fasted or diabetic rats (63–66). Also in chicken, fasting increased IGFBP-2 expression in the liver and gizzard, and insulin administration decreased IGFBP-2 expression in both tissues (67). By contrast, in the brain, fasting efficiently reduced expression of...
IGFBP-2 mRNA as shown by Kita and coworkers in chicken (14). Insulin suppression of IGFBP-2 expression was also observed in hepatocytes isolated from rats (68, 69). However, dietary control of IGFBP-2 expression seems to occur also in non-hepatic cells, since insulin significantly increased mRNA expression of IGFBP-2 in primary rat astroglial cells (15). Nutritional regulation of IGFBP-2 also expands into the ovaries from sheep, where dietary factors (infusion of glucose and glucosamine or lupine supplementation) increased its expression in follicular granulosa cells. Thereby, higher IGFBP-2 levels correlated with the number of atretic follicles (148).

SUMMARY AND CONCLUSION

Expression of IGFBP-2 is depending on trophic signals from the IGF/PI3K pathway, dietary factors, and oxygen. However, in a wide variety of tissues, steroids have been identified as effectors of IGFBP-2 expression. Steroids may impact on the level of IGFBP-2 mRNA and protein expression or stability. In addition to reproductive organs particularly within the brain steroids have major effects on the expression of IGFBP-2. Above all other steroids, E2 appears to have a particular function for the control of IGFBP-2. Furthermore, in different tissues E2 seems to modulate IGF-signaling pathways. With respect to IGFBP-2 levels, interactions of GH/IGF-signals and steroid signals seem to exist on the level of cytosolic signal transduction but also on the level of RNA transcription within the cell nucleus. Those interactions might provide novel molecular targets in the prevention or therapy of malignant or metabolic diseases (2–7). Looking back at 25 years of IGFBP-2 research, the dominant role of E2 for regulation of IGFBP-2 activity is intriguing. To date, the understanding of functional interrelations between IGFBP-2 and steroids is likely just in its beginnings.

ACKNOWLEDGMENTS

This work was supported by a grant from the Deutsche Forschungsgemeinschaft (DFG HO20053/6-1).

REFERENCES

1. Binkert C, Landwehr J, Mary JL, Schwander J, Heinrich G. Cloning, sequence expression and conversion of a cDNA encoding a novel insulin-like growth factor binding protein (IGFBP-2). EMBO J (1989) 8:2497–502.
2. Zhang W, Fuller G. IGFBP-2 as a brain tumor oncogene. Cancer Biol Ther (2007) 6:995–96.
3. Chi F, Wu R, Zeng YC, Xing R, Liu Y. Circulation insulin-like growth factor peptides and colorectal cancer risk: an updated systematic review and meta-analysis. Mol Biol Rep (2013) 40:5853–90. doi:10.1007/s11033-012-2432-z
4. Rowlands MA, Gunnell D, Harris R, Vatten LJ, Holly JM, Martin RM. Circulating insulin-like growth factor peptides and prostate cancer risk: a systematic review and meta-analysis. Int J Cancer (2009) 124:2416–29. doi:10.1002/ijc.24020
5. Fukushima T, Kataoka H. Roles of insulin-like growth factor binding protein-2 (IGFBP-2) in glioblastoma. Anticancer Res (2007) 27:3685–92.
6. Fottner C, Hoeflich A, Wolf E, Weber MM. Role of the insulin-like growth factor system in adrenocortical growth control and carcinogenesis. Horm Metab Res (2004) 36:397–405. doi:10.1055/s-2004-814563
7. Firth SM, Baxter RC. Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev (2002) 23:824–54. doi:10.1210/er.2001-0033
8. Hoeflich A, Reissinger R, Lahn H, Kiess W, Bluem WF, Kolb HJ, et al. Insulin-like growth factor-binding protein 2 in tumorigenesis, promoter or protector? Cancer Res (2001) 61:8601–10.
9. Dunlap SM, Celestino J, Wang H, Jiang R, Holland EC, Fuller GN, et al. Insulin-like growth factor binding protein 2 promotes glioma development and progression. Proc Natl Acad Sci U S A (2007) 104:11736–41. doi:10.1073/pnas.0703145104
10. Diedl D, Hessel E, Oesterle D, Renner-Müller I, Elminger M, Langhammer M, et al. IGFBP-2 overexpression reduces the appearance of dysplastic aberrant crypt foci and inhibits growth of adenomas in chemically induced colorectal carcinogenesis. Int J Cancer (2009) 124:2220–5. doi:10.1002/ijc.24193
11. Ruccarelli E, Hernandez ER, Hurwit A, Kokia E, Rosenfeld RG, Schwaner I, et al. The ovarian expression of the antigonadotropic insulin-like growth factor binding protein-2 is thca-interstitial cell-selective: evidence for hormonal regulation. Endocrinology (1991) 129:2266–8. doi:10.1210/en-129-4-2266
12. Giudice LC, Milkowski DA, Lamson G, Rosenfeld RG, Irwin JC. Insulin-like growth factor binding proteins in human endometrium: steroid-dependent messenger ribonucleic acid expression and protein synthesis. J Clin Endocrinol Metab (1991) 72:779–87. doi:10.1210/jcem-72-4-779
13. Firth SM, Baxter RC. Cellular actions of the insulin-like growth factor binding protein (IGFBP-2) promoter. Control of IGFBP-2 expression in primary rat astroglial cells (15). Nutritional regulation of IGFBP-2 also expands into the ovaries from sheep, where dietary factors (infusion of glucose and glucosamine or lupine supplementation) increased its expression in follicular granulosa cells. Thereby, higher IGFBP-2 levels correlated with the number of atretic follicles (148).

www.frontiersin.org
April 2014 | Volume 5 | Article 43 | 5
CONTROL OF IGFBP-2 EXPRESSION
27. Echternkamp SE, Howard HJ, Roberts AJ, Grizzle J, Wise T. Relationships among concentrations of steroids, insulin-like growth factor-I, and insulin-like growth factor binding proteins in ovian follicular fluid of beef cattle. *Biol Reprod* (1994) 51:971–80. doi:10.1095/biolreprod51.5.971

28. Ginther OJ, Bergfelt DR, Harvey RW, Clemmons DR, White AR. Effect of somatotropin and/or equine chorionic gonadotropin on insulin-like growth factor-binding protein secretion by human granulosa luteal cells in a polycystic ovary-like environment. *Reproduction* (2003) 125:869–81. doi:10.1530/reprod.1.00557

29. Stanko RL, Colhick WS, Shaw DW, Harvey RW, Clemmons DR, Whitacre MD, et al. Effect of somatotropin and/or equine chorionic gonadotropin on serum and follicular insulin-like growth factor I and insulin-like growth factor binding proteins in cattle. *Biol Reprod* (1994) 50:290–300. doi:10.1095/biolreprod50.2.290

30. Davidson TR, Chamberlain CS, Bridges TS, Spicer LJ. Effect of follicle size on insulin-like growth factors and the IGF-binding proteins by equine ovarian granulosa cells. *Biol Reprod* (2002) 66:1640–8. doi:10.1095/biolreprod66.6.1640

31. Muñoz-Gutiérrez M, Findlay PA, Adam CL, Wax G, Campbell BK, Kendall NR, et al. The ovarian expression of mRNAs for aromatase, IGF-I receptor, IGF-binding protein-2, -4 and -5, and leptin and leptin receptor in cycling ewes at three days of leptin infusion. *Reproduction* (2005) 130:869–81. doi:10.1530/reprod.1.00557

32. Cataldo NA, Fujimoto YV, Jaffe RB. Interferon-gamma and activin A promote insulin-like growth factor-binding protein-2 and -4 accumulation by human luteinizing granulosa cells, and interferon-gamma promotes their apoptosis. *J Clin Endocrinol Metab* (1998) 83:179–86. doi:10.1210/jc.83.1.14481

33. Greisen S, Flyvbjerg A, Ledet T, Ovesen P. Regulation of insulin-like growth factor gene expression in pig uterus. *Endocrinology* (2005) 147:2399–410. doi:10.1210/en.2005-1570

34. Chen W, Wang Y, Li W, Lin H. Insulin-like growth factor binding protein-2 and -4 accumulation by human insulin-like growth factors (IGFs) and IGF-binding proteins of the pig uterus and vagina. *Am J Physiol Endocrinol Metab* (2005) 289:E573–84. doi:10.1152/ajpendo.00454.2004

35. Martin JL, Baxter RC. Expression of insulin-like growth factor binding protein-2 by MCF-7 breast cancer cells is regulated through the phosphatidylinositol 3-kinase/akt/mammalian target of rapamycin pathway. *Endocrinology* (2007) 148:2352–41. doi:10.1210/en.2006-1335

36. Chen W, Wang Y, Li W, Lin H. Insulin-like growth factor-binding protein-2 and -4 accumulation by human insulin-like growth factors (IGFs) and IGF-binding proteins of the pig uterus and vagina. *Am J Physiol Endocrinol Metab* (2005) 289:E573–84. doi:10.1152/ajpendo.00454.2004

37. Mireuta M, Darnel A, Pollak M. IGFBP-2 expression in MCF-7 cells is regulated by the PI3K/AKT/mTOR pathway through Sp1-induced increase in transcription. *Growth Factors* (2010) 28:243–55. doi:10.1097/01.mrf.000037454272

38. Chan TW, Pollak M, Huyhn H. Inhibition of insulin-like growth factor signal pathways in mammary gland by pure antiestrogen ICI 182,780. *Clin Cancer Res* (2002) 7:2545–54.

39. Sheikhi MS, Shao ZM, Hussain A, Clemmons DR, Chen JC, Roberts CT Jr, et al. Regulation of insulin-like growth factor-binding-protein-1, -2, 3, 4, 5, and 6; synthesis, secretion, and gene expression in estrogen receptor-negative human breast carcinoma cells. *J Cell Physiol* (1993) 155:556–67. doi:10.1002/jcp.1041550314

40. Martin JL, Baxter RC. Expression of insulin-like growth factor binding protein-2 by MCF-7 breast cancer cells is regulated through the phosphatidylinositol 3-kinase/AKT/mammanl target of rapamycin pathway. *Endocrinology* (2007) 148:2352–41. doi:10.1210/en.2006-1335

41. Milewicz T, Grigorkaszcuk EL, Szefko K, Augustowska K, Kryszek J, Rys J. Lack of synergy between estrogen and progesterone on local IGF-I, IGFBP-3 and IGFBP-2 secretion by both hormone-dependent and hormone-independent breast cancer explants in vitro. Effect of tamoxifen and megestrol acetate (RU 486). *Growth Horm IGF Res* (2005) 15:140–7. doi:10.1016/j.ghire.2004.12.006

42. Dubois V, Couassi D, Schonne E, Remacle C, Trosset M. Intracellular levels and secretion of insulin-like-growth-factor-binding proteins in MCF-7, MCF-7/AT and MDA-MB-231 breast cancer cells. Differential modulation by estrogens in serum-free medium. *Eur J Biochem* (1995) 232:47–53. doi:10.1111/j.1432-1033.1995.tb0779.x

43. Fog CK, Christensen II, Lykkefeldt AE. Characterization of a human breast cancer cell line, MCF-7/RU38SR-1, resistant to the pure antiestrogen RU 58,668. *Breast Cancer Res Treat* (2005) 91:133–44. doi:10.1007/s10545-004-5871-γ

44. Korc-Grodzicki B, Ren N, Hill R. Effects of estradiol on the expression and production of IGFBP-2 by B3230/A5 mammary tumor cells. *Oncol Res* (1996) 8:473–83.

45. Thomas LN, Wright AS, Lazier CB, Cohen P, Rittmaster RS. Prostatic involution in men taking finasteride is associated with elevated levels of insulin-like growth factor-binding proteins (IGFBPs)-2, -4, and -5. *Prostate* (2000) 42:203–10. doi:10.1002/sjc.10597-0455.4203

46. Le H, Arnold JT, McCann KF, Blackman MR, DHT and testosterone, but not DHEA or E2, differentially modulate IGF-I, IGFBP-2, and IGFBP-3 in human prostatic stromal cells. *Am J Physiol Endocrinol Metab* (2006) 290:E592–60. doi:10.1152/ajpendo.00451.2005

47. Martin JL, Patterson SL. Insulin-like growth factor binding protein-3 is regulated by dihydrotestosterone and stimulates deoxyribonucleic acid synthesis and cell proliferation in LNCaP prostate carcinoma cells. *Endocrinology* (2000) 141:213–20. doi:10.1210/endo.141.2.75734

48. Arnold TL, Le H, McCann KF, Blackman MR. Comparative effects of DHEA vs. testosterone, dihydrotestosterone, and estradiol on proliferation and gene expression in human LNCaP prostate cancer cells. *Am J Physiol Endocrinol Metab* (2005) 288:E583–74. doi:10.1152/ajpendo.00454.2004

49. Degraf DJ, Aguiar AA, Chen Q, Adams LK, Williams BJ, Sikes RA. Androgen-mediated translational and posttranslational regulation of IGFBP-2 in androgen-sensitive LNCaP human prostate cancer cells. *Am J Transl Res* (2010) 2:200–8.

50. Kyama S, Morrison K, Zellweger T, Akbari M, Cox M, Yu D, et al. Castration-induced increases in insulin-like growth factor-binding protein-2 promotes proliferation of androgen-independent human prostate LNCaP tumors. *Cancer Res* (2003) 63:3575–84.

51. Degraf DJ, Malik M, Chen Q, Miyako K, Rejo L, Aguiar AA, et al. Hormonal regulation of IGFBP-2 protein synthesis is attenuated with progression to androgen insensitivity in the LNCaP progression model. *J Cell Physiol* (2007) 213:261–8. doi:10.1002/jcp.21123

52. Stewart JV, Wiegand NL. Role of insulin-like growth factor binding proteins in the cardiovascular system. *Adv Exp Med Biol* (2006) 566:17–51.

53. Pang W, Naggel ML, Lin T, Shimazaki S, Ling N. Insulin-like growth factor-binding protein-2: the effect of human chorionic gonadotropin on its gene regulation and protein secretion and its biological effects in rat Leydig cells. *Endocrinology* (1994) 96:89–96. doi:10.1210/mend.8.1.7512196

54. Mireuta M, Darnel A, Pollak M. IGFBP-2 expression in MCF-7 cells is regulated by the PI3K/AKT/mTOR pathway through Sp1-induced increase in transcription. *Growth Factors* (2010) 28:243–55. doi:10.1097/01.mrf.000037454272
62. Hedbacker K, Birouk K, Wysoki RW, Aslmaez E, Ahima RS, Farooqi JS, et al. Antidiabetic effects of IGBP2, a leptin-regulated gene. Cell Metab (2010) 11:111–22. doi:10.1016/j.cmet.2009.11.007

63. Ooi GT, Olowoloki CC, Brown AL, Becker RE, Untergerm TM, Rechner MM. Different tissue distribution and hormonal regulation of messenger RNAs encoding rat insulin-like growth factor-binding proteins-1 and -2. Mol Endocrinol (1990) 4:321–8. doi:10.1210/mend-4-2-321

64. Strauss DS, Takahashi CO. Effect of dietary protein deprivation on insulin-like growth factor (IGF)-I and -II, IGF binding protein-2, and serum albumin gene expression in rat. Endocrinology (1990) 127:1849–60. doi:10.1210/endo-127-4-1849

65. Tseng LY, Ooi GT, Brown AL, Strauss DS, Rechner MM. Transcription of the insulin-like growth factor-binding protein-2 gene is increased in neonatal and fasted adult rat liver. Mol Endocrinol (1992) 6:1995–201. doi:10.1210/mend-6.8.1386892

66. Boni-Schnetzler M, Binz K, Mary JL, Schmid C, Schwander J, Froesch ER. Regulation of hepatic expression of IGF-I and fetal IGF binding protein mRNA in streptozotocin-diabetic rats. FEBS Lett (1989) 251:253–6. doi:10.1016/0014-5793(89)81465-6

67. Nagao K, Aman Y, Murai A, Sasaki T, Saito N, Okumura J, et al. Insulin suppression increases in insulin-like growth factor binding protein-2 gene expression stimulated by fasting in the chicken. Br Poult Sci (2001) 42:501–4. doi:10.1080/000716601200706762

68. Schmid C, Schläpfer I, Waldvogel M, Meier PJ, Schwander J, Böni-Schnetzler M, et al. Differential regulation of insulin-like growth factor binding protein (IGFBP-2) mRNA in liver and bone cells by insulin and retinoic acid in vitro. FEBS Lett (1992) 303:205–9. doi:10.1016/0014-5793(92)80520-Q

69. Boni-Schnetzler M, Schmid C, Mary JL, Zimmerli B, Meier PJ, Zafir J, et al. Insulin regulates the expression of the insulin-like growth factor binding protein-2 mRNA in rat hepatocytes. Mol Endocrinol (1990) 4:1320–6. doi:10.1210/mend-4-9-1320

70. Crespi EJ, Steckler TL, Mohankumar PS, Padmanabhan V. Prenatal exposure to excess testosterone modifies the developmental trajectory of the insulin-like growth factor system in female sheep. J Physiol (2006) 572:119–30.

71. Rejinders CM, Bravenboer N, Holzmann PJ, Bhoelan F, Blankenstein MA, Lips P. In vivo mechanical loading modulates insulin-like growth factor binding protein-2 gene expression in rat osteotyes. Calcif Tissue Int (2007) 80:137–43. doi:10.1007/s00223-006-0077-4

72. Boisclair YR, Yang YW, Stewart JM, Rechner MM. Insulin-like growth factor-I and insulin stimulate the synthesis of IGBP-2 protein in a human embryonic kidney cell line. Growth Regul (1994) 4:35–46.

73. Cazals V, Nabeeyrat E, Corroyer S, de Keyzer Y, Clement A. Role for NF-kappa B in the induction of insulin-like growth factor binding protein II and the stimulation of insulin-like growth factor binding protein-6 in conjunction with growth suppression of HT-29 colon cancer cells. Mol Cell Endocrinol (2001) 183:141–9. doi:10.1016/S0303-7207(01)00598-6

74. Averbukh E, Weiss O, Halpert Y, Tanko R, Moshe R, Nepsh H, et al. Gene expression of insulin-like growth factor-I, its receptor and binding proteins in retina under hypoxic conditions. Metabolism (1998) 47:1331–6. doi:10.1016/S0026-0495(98)90300-6

75. Nachtrieb G, Czerwinski M, Poss KD. Sexually dimorphic fin regeneration in zebrafish controlled by androgen/GSK3 signaling. Curr Biol (2011) 21:1912–7. doi:10.1016/j.cub.2011.09.050

76. Song S, Lee CY, Green ML, Chung CS, Simmen RC, Simmen FA. The unique endometrial expression and genomic organization of the porcine IGBP2-2 gene. Mol Cell Endocrinol (1996) 120:193–202. doi:10.1016/0026-0495(96)03837-3

77. Kwak I, Song S, Blum JL, Simmen RC, Simmen FA. Enhancer- and silencer-like sequences that mediate insulin-like growth factor binding protein-2 gene expression in uterine cells of pregnant rats: DNA Cell Biol (2006) 25:18–28. doi:10.1089/dcb.2006.25.6

78. Badinga L, Song S, Simmen RC, Simmen FA. A distal regulatory region of the insulin-like growth factor binding protein-2 (IGFBP-2) gene and identification of a functional promoter lacking a TATA box. Mol Endocrinol (1990) 4:2039–51. doi:10.1210/mend-4-12-2039

79. Boisclair YR, Brown AL, Casola S, Rechner MM. Three clustered Sp1 sites are required for efficient transcription of the TATA-less promoter of the gene for insulin-like growth factor-binding protein-2 from the rat. J Biol Chem (1993) 6:24892–901.

80. Boisclair YR, Casola S, Rechner MM. The unique endometrial expression and genomic organization of the porcine IGBP-2 gene. Mol Cell Endocrinol (1996) 120:193–202. doi:10.1016/0026-0495(96)03837-3

81. Hilleson-Gayne CK, Clapper JA. Effects of decreased estradiol-17β on expression of insulin-like growth factor-binding protein-2 in human glioblastoma cells. Exp Cell Res (2007) 31:4228–32. doi:10.1016/j.yexcr.2007.04.001
reduces both invasiveness and expression of progression-associated gene CD24.

78. Moore LM, Holmes KM, Smith SM, Wu T, Choungrouva E, Uherekoon L, et al. IGFBP2 is a candidate biomarker for Inktas-Arf status and a therapeutic target for high-grade gliomas. *Proc Natl Acad Sci U S A* (2009) 106:16675–9. doi:10.1073/pnas.0900870106

79. Altinok N, Ersbor M, Koyaturk M. Estradiol induces INK-dependent apoptosis in glioblastoma cells. *Onco Lett* (2011) 2:1281–5.

80. DeMambro VE, Maale L, Wai C, Kawaii M, Cassella T, Rosen CJ, et al. Insulin-like growth factor-binding protein-2 is required for osteoclast differentiation. *J Bone Miner Res* (2012) 27:390–400. doi:10.1002/jbmr.545

81. Heald A, Kaushal K, Anderson S, Redpath M, Durrington PN, Selby PL, et al. Effects of hormone replacement therapy on insulin-like growth factor (IGF)-I, IGF-II and IGF binding protein (IGFBP)-1 to IGFBP-4: implications for cardiovascular risk. *Cytokine Growth* (2005) 20:176–82. doi:10.1080/0955390400270406

82. Rooman RP, De Beeck LO, Martinién M, van Doorn J, Mohan S, Du Caju MV. Ethinyloestradiol and testosterone have divergent effects on circulating IGF system components in adolescents with constitutional tall stature. *Eur J Endocrinol* (2005) 152:597–604. doi:10.1530/eje.0.11880

83. Munner T, Rosen CJ, Harmon SM, Pabst KM, St Clair C, Soktin JD, et al. Effects of GH and/or sex steroids on circulating IGF-I and IGFBPs in healthy, aged women and men. *Am J Physiol Endocrinol Metab* (2009) 290:E1006–13. doi:10.1152/ajpendo.90076.2005

84. Howard HJ, Ford JI. Relationships among concentrations of steroids, inhibin, insulin-like growth factor-1 (IGF-I), and IGF-binding proteins during follicular development in weaned sow. *Biol Reprod* (1992) 47:193–201. doi:10.1095/biolreprod47.2.193

85. Walters KA, Armstrong DG, Telfer EE. Bovine mural granulosa cells, and not thecal cells, contribute to expression of components of the pig uterine insulin-like growth factor system. *Horm IGF Res* (2006) 5:224–39. doi:10.1016/j.ghir.2006.06.005

86. Simmen FA, Simmen RC, Geisert RD, Martinat-Botte F, Bazer FW, Terqui M. Differential expression, during the estrous cycle and pre- and postimplantation conceptus development, of messenger ribonucleic acid encoding components of the pituitary insulin-like growth factor system. *Endocrinology* (1992) 130:1547–56. doi:10.1210/en.130.3.1547

87. Geisert RD, Chamberlain CS, Vonahnke KA, Malayer JR, Spicer LJ. Possible role of kallikrein in proteolysis of insulin-like growth factor binding proteins during the oestrous cycle and early pregnancy in pigs. *Reproduction* (2001) 121:79–86. doi:10.1530/rep.0.1210719

88. Elmlinger MW, Grund R, Buck M, Wollmann HA, Feist N, Weber MM, et al. Limited proteolysis of the IGF binding protein-2 (IGFBP-2) by a specific serine protease activity in early breast milk. *Pediatr Res* (1999) 46:76–81. doi:10.1203/00006450-199906400-00013

89. Lee CY, Bazer FW, Simmen FA. Expression of components of the insulin-like growth factor system in pig mammary glands and serum during pregnancy and pseudopregnancy: effects of oestrogen. *J Endocrinol* (1993) 137:273–83. doi:10.1677/joe.0.1370473

90. Maxwell PD, van den Berg HW. Changes in the secretion of insulin-like growth factor binding proteins-2 and -4 associated with the development of tamoxifen resistance and estrogen independence in human breast cancer cell lines. *Cancer Lett* (1999) 139:121–7. doi:10.1016/S0304-3835(99)00009-9

91. Juncker-Jensen A, Lykkefeldt AE, Juncker J, Stijnen T, Drop SL, de Muinck Keizer-Schrama SM. Free dissociable insulin-like growth factor I (IGF-I), total IGF-I and their binding proteins in girls with Turner syndrome during long-term growth hormone treatment. *Clin Endocrinol (Oxf)* (2006) 65:5310–9. doi:10.1111/j.1365-2265.2005.02594.x

92. Katz LE, Liu F, Baker B, Agus MS, Nunn SE, Hintz RL, et al. The effect of growth hormone treatment on the insulin-like growth factor axis in a child with nonisollet cell tumor hypoglycemia. *J Clin Endocrinol Metab* (1996) 81:1141–6. doi:10.1210/jcem.81.3.772354

93. Kassem M, Brinen K, Moskilde L, Blum WM, Flyvbjerg A. Effects of growth hormone treatment on serum levels of insulin-like growth factors (IGFs) and IGF binding proteins 1-4 in postmenopausal women. *Clin Endocrinol (Oxf)* (1998) 49:747–56. doi:10.1111/j.1365-2265.1998.00606.x

94. Coschigano KT, Holland AM, Riders ME, List EO, Flyvbjerg A, Kopchick JJ. Deletion, but not antagonism, of the mouse growth hormone receptor results in severely decreased body weights, insulin, and insulin-like growth factor I levels and increased life span. *Endocrinology* (2003) 144:3799–810. doi:10.1210/en.2003-0374

95. Young SC, Underwood LE, Celinski A, Clemmons DR. Effects of recombinant insulin-like growth factor-I (IGF-I) and growth hormone on serum IGF-binding proteins in castrated adults. *J Clin Endocrinol Metab* (1992) 75:603–8. doi:10.1210/jc.75.2.603

96. Lee PD, Durham SK, Martinez V, Vasconez O, Powell DR, Guevara-Agurire J. Kinetics of insulin-like growth factor (IGF) and IGF-binding protein responses to a single dose of growth hormone. *J Clin Endocrinol Metab* (1997) 82:2266–74. doi:10.1210/jc.82.7.4048

97. Kicman AT, Miedl JP, Polew J, Wood JP, Laidler F, et al. Serum IGF-I and IGF binding proteins 2 and 3 as potential markers of doping with human GH. *Clin Endocrinol (Oxf)* (1997) 47:43–50. doi:10.1046/j.1365-2265.1997.211036.x

98. Guha N, Erotkoutrou-Mulligan I, Nevitt SP, Francis M, Bartlett C, Cowan DA, et al. Biochemical markers of recombinant human insulin-like growth factor-I (rhIGF-I)/rhIGF binding protein 3 (rhIGFBP-3) misuse in athletes. *Drug Test Anal* (2011) 3:45–63. doi:10.1002/dta.1562

99. Donahue LR, Watson G, Beamer WG. Regulation of metabolic water and protein compartments by insulin-like growth factor-I and testosterone in growth hormone-deficient lit/lit mice. *J Endocrinol* (1993) 139:431–9. doi:10.1677/joe.0.1390431

100. McGrann DR, McCann L, Ninniou TD, Abrial T. Differential effects of GH stimulation on fasting and prandial metabolism and plasma IGFs and IGF-binding proteins in insulin-resistant lean and postobese women. *J Endocrinol* (1997) 154:329–46. doi:10.1677/joe.0.1540329

101. Thrallk I, Quintaing T, Baker L, Litton J, Dwigun K, Reasmo N, et al. Dual hormonal replacement therapy with insulin and recombinant human insulin-like growth factor (IGF-I) in insulin-dependent diabetes mellitus: effects on the growth hormone/IGF-I and IGF-I receptor axis. *J Clin Endocrinol Metab* (2007) 82:1181–7. doi:10.1210/jc.2007-0259

102. Wolf E, Jehle PM, Weber MM, Sauerwein H, Daxenberger A, Breier BH, et al. Human insulin-like growth factor I (IGF-I) produced in the mammary gland of an insulin receptor knockout mouse. *Endocrinology* (1992) 130:387–97. doi:10.1210/endo.130.5.387

103. Metzger F, Sajid W, Saengler S, Staedemermaier C, van der Poel C, Sobotka B, et al. Separation of fast from slow anabolism by site-specific PEGylation of insulin-like growth factor-1 (IGF-I). *J Biolog Chem* (2011) 286:19501–10. doi:10.1074/jbc.M111.271189

104. Wolf E, Kramer R, Blum WF, Poll F, Brem G. Consequences of posttranslationally modified insulin-like growth factor-II in transgenic mice: endocrine changes and effects on body and organ growth. *Endocrinology* (1994) 135:1877–86. doi:10.1210/en.135.5.1877

105. Rogler CE, Yang D, Rosetti L, Donohoe J, Alt E, Chang CJ, et al. Altered body composition and increased frequency of diverse malignancies in insulin-like growth factor-II transgenic mice. *J Biolog Chem* (1994) 269:13779–84.
